Which Obesity Drugs Actually Matter for Sleep Apnea?

Which Obesity Drugs Are Approved for Sleep Apnea?

One. As of March 9, 2026, Zepbound (tirzepatide) by Eli Lilly is the only obesity drug with an FDA-approved indication for obstructive sleep apnea. The FDA granted the approval on December 20, 2024, for the treatment of moderate-to-severe OSA in adults with obesity. This made Zepbound the first prescription medicine ever approved specifically for OSA.

Before this approval, the standard of care for OSA was continuous positive airway pressure (CPAP) therapy. No prescription drug had demonstrated sufficient efficacy in a controlled trial to earn an FDA indication. Zepbound changed that.

No other GLP-1 receptor agonist, dual agonist, or triple agonist has an FDA-approved OSA indication. Semaglutide (Wegovy/Ozempic) is not approved for sleep apnea. CagriSema and survodutide have no OSA-specific trial data. Retatrutide is actively studying the question but has not reported results.

What Did the SURMOUNT-OSA Trial Show?

The SURMOUNT-OSA trial was a randomized, double-blind, placebo-controlled Phase 3 study evaluating tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. The trial had two arms: one with patients not using CPAP at baseline, and one with patients using CPAP.

The headline results were significant. Tirzepatide produced approximately 18% body weight loss and reduced the apnea-hypopnea index (AHI) by 51–52% versus baseline. AHI is the primary clinical measure of sleep apnea severity — it counts the number of apnea and hypopnea events per hour of sleep.

Perhaps more notable: 42–50% of patients achieved disease remission, defined as an AHI below 5 events per hour. An AHI below 5 is clinically considered normal — meaning nearly half the patients in the trial no longer met the diagnostic threshold for sleep apnea.

These results were robust enough for the FDA to grant a new indication — the first time any drug had cleared that bar for OSA.

Is Retatrutide Being Studied for Sleep Apnea?

Yes. Eli Lilly’s TRIUMPH-3 Phase 3 trial includes obstructive sleep apnea as a pre-specified endpoint. This means the trial was designed from the start to measure OSA outcomes — it is not a post-hoc analysis or an observational signal.

As of March 2026, no OSA-specific results from TRIUMPH-3 have been reported. The Phase 3 readout is expected in 2026. Given retatrutide’s triple-agonist mechanism (GLP-1 + GIP + glucagon receptor), there is scientific interest in whether the glucagon component adds benefits beyond what tirzepatide’s dual mechanism achieves for OSA. Our retatrutide vs tirzepatide vs CagriSema comparison details how these mechanisms diverge across efficacy endpoints.

In Phase 2, retatrutide demonstrated up to 24.2% weight loss at 48 weeks — substantially higher than tirzepatide’s ~18% in SURMOUNT-OSA. If TRIUMPH-3 shows proportionally greater AHI reduction, retatrutide could become the second obesity drug approved for OSA and potentially the most effective pharmacological option available. For retatrutide titration protocols and dosing schedules used in the TRIUMPH program, see the retatrutide dosage guide. For a detailed analysis of retatrutide adverse events including the dysesthesia signal, see our retatrutide side effects profile.

Why Does Weight Loss Improve Sleep Apnea?

Approximately 70% of patients with obstructive sleep apnea are obese. The connection is mechanical: excess adipose tissue around the upper airway increases pharyngeal collapsibility during sleep, leading to repeated airway obstruction — the hallmark of OSA.

Clinical data consistently shows that 10–15% body weight loss can significantly reduce AHI scores. The mechanism is straightforward: reducing fat deposits around the pharynx and tongue base decreases the mechanical load on the airway, reducing the frequency and severity of obstructive events.

This is why obesity drugs that produce meaningful weight loss have inherent potential as OSA treatments. However, the relationship is not perfectly linear — some patients with significant weight loss still have residual OSA, which is why the FDA requires controlled trial evidence rather than extrapolating from weight-loss data alone. For a wider look at GLP-1 use beyond diabetes, see our GLP-1 in non-diabetics research overview.

CPAP remains the standard of care, but real-world adherence is approximately 50%. Many patients cannot tolerate the device, use it inconsistently, or abandon it entirely. This adherence gap is what makes pharmacological alternatives like Zepbound clinically significant — not as a CPAP replacement, but as a complement or alternative for patients who cannot maintain CPAP therapy.

Do GLP-1 Drugs Improve Sleep Apnea Without an OSA Approval?

Some observational and retrospective data suggest that GLP-1 receptor agonists may improve sleep apnea markers secondary to weight loss. This is mechanistically plausible — any drug that produces 10–15%+ weight loss should reduce AHI in obese patients with OSA.

However, observational data is not the same as a controlled trial with an OSA-specific primary endpoint. The FDA approved Zepbound for OSA based on SURMOUNT-OSA — a purpose-designed, randomized, placebo-controlled study that measured AHI reduction as a primary outcome. No other GLP-1 agonist has this level of evidence for OSA.

Semaglutide (Wegovy/Ozempic) is the most commonly prescribed GLP-1 for obesity, but Novo Nordisk has not announced an OSA-specific clinical trial. Without controlled data, any claims about semaglutide treating sleep apnea are extrapolation, not evidence. Clinicians may observe OSA improvement in patients taking semaglutide, but this does not constitute an approved indication. For a comparison of adverse event profiles across these compounds, see our Ozempic vs Mounjaro vs Wegovy side effects review.

What Should Researchers Watch Next?

Three developments will shape the OSA treatment landscape in 2026 and beyond:

1. TRIUMPH-3 readout for retatrutide. If Eli Lilly reports positive OSA data from TRIUMPH-3, retatrutide could become the second FDA-approved drug for sleep apnea — and potentially the most effective, given its superior weight-loss profile versus tirzepatide. The Phase 3 readout is expected in 2026.

2. Real-world Zepbound OSA data. Post-approval studies and real-world evidence will clarify how Zepbound performs outside controlled trial conditions — particularly on CPAP discontinuation rates and long-term AHI durability.

3. Whether competitors pursue OSA indications. Novo Nordisk (semaglutide), Amgen, and Zealand/Roche have not announced OSA-focused trials. If TRIUMPH-3 is positive, competitive pressure may drive additional OSA programs. Until then, Zepbound remains the only approved pharmacological option. Explore the full landscape of metabolic research compounds in our best research peptides 2026 guide.